CA2952061A1 - Use of serelaxin to reduce gdf-15 - Google Patents

Use of serelaxin to reduce gdf-15 Download PDF

Info

Publication number
CA2952061A1
CA2952061A1 CA2952061A CA2952061A CA2952061A1 CA 2952061 A1 CA2952061 A1 CA 2952061A1 CA 2952061 A CA2952061 A CA 2952061A CA 2952061 A CA2952061 A CA 2952061A CA 2952061 A1 CA2952061 A1 CA 2952061A1
Authority
CA
Canada
Prior art keywords
serelaxin
gdf
patient
day
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2952061A
Other languages
English (en)
French (fr)
Inventor
Margaret Forney Prescott
Yiming Zhang
Marion Dahlke
Thomas Severin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2952061A1 publication Critical patent/CA2952061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
CA2952061A 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15 Abandoned CA2952061A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (1)

Publication Number Publication Date
CA2952061A1 true CA2952061A1 (en) 2015-12-17

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952061A Abandoned CA2952061A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Country Status (11)

Country Link
US (2) US20170100460A1 (cg-RX-API-DMAC10.html)
EP (1) EP3154559B1 (cg-RX-API-DMAC10.html)
JP (1) JP6820748B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170018829A (cg-RX-API-DMAC10.html)
CN (1) CN106413740A (cg-RX-API-DMAC10.html)
AU (2) AU2015273097A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016028833A2 (cg-RX-API-DMAC10.html)
CA (1) CA2952061A1 (cg-RX-API-DMAC10.html)
MX (1) MX2016016414A (cg-RX-API-DMAC10.html)
RU (1) RU2016147122A (cg-RX-API-DMAC10.html)
WO (1) WO2015189790A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
EP3988031A4 (en) * 2019-06-20 2022-08-10 Sony Group Corporation Information processing device, information processing method, and program

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2017519008A (ja) 2017-07-13
BR112016028833A2 (pt) 2017-08-22
CN106413740A (zh) 2017-02-15
KR20170018829A (ko) 2017-02-20
JP6820748B2 (ja) 2021-01-27
AU2018202289A1 (en) 2018-04-26
RU2016147122A (ru) 2018-07-16
US20190022189A1 (en) 2019-01-24
RU2016147122A3 (cg-RX-API-DMAC10.html) 2019-01-28
EP3154559B1 (en) 2021-09-01
AU2015273097A1 (en) 2016-11-17
MX2016016414A (es) 2017-04-10
WO2015189790A1 (en) 2015-12-17
EP3154559A1 (en) 2017-04-19
US20170100460A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
US20190022189A1 (en) Use of serelaxin to reduce gdf-15
Jensen et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial
Dayem et al. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients–DACAMI (a randomized controlled clinical trial)
AU2021215150B2 (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
Borghi et al. Hyperuricemia: a novel old disorder—relationship and potential mechanisms in heart failure
EP2885641B1 (en) Methods for predicting risk of developing hypertension
Nakazato et al. Association of calciprotein particles measured by a new method with coronary artery plaque in patients with coronary artery disease: a cross-sectional study
CN113423395A (zh) 通过增加血清及血浆epa及dpa水平来降低经他汀治疗的受试者的心血管事件的风险的方法
Uematsu et al. Sustained myocardial production of stromal cell-derived factor-1α was associated with left ventricular adverse remodeling in patients with myocardial infarction
Albiero et al. Exploring neutrophils as therapeutic targets in cardiometabolic diseases
Zhang et al. Effectiveness and safety of intravenous nicorandil application in patients with acute heart failure with low baseline blood pressure
Inoue et al. Influence of low-grade inflammation on plasma B-type natriuretic peptide levels
Yoshizaki et al. Angiotensin II receptor blockers suppress the release of stromal cell-derived factor-1α from infarcted myocardium in patients with acute myocardial infarction
Hartmann et al. Myocardial Injury in Post Mortem Biopsies of Patients with COVID-19
BA BEST ABSTRACTS SITZUNG
EA042257B1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
HK40060705A (en) Methods of reducing the risk of a cardiovascular event in a statin-treated subject by increasing serum and plasma epa and dpa levels
Fusaro et al. Cardiovascular complications in CKD 5D
Boman et al. Effects of carvedilol versus metoprolol on hemostasis and fibrinolysis in patients with chronic heart failure

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831